AstraZeneca Pushes Deeper into CDx Space with New Collaboration

The Cambridge, UK-based company is teaming up with Amoy Diagnostics to develop CDx offerings.

MDDI Staff

April 20, 2022

1 Min Read
AstraZeneca headquaters building.png
Image courtesy of Helen Sessions / Alamy Stock Photo

AstraZeneca is making a bigger push into the companion diagnostics space. The pharmaceutical company is teaming up with Shanghai, China-based Amoy Diagnostics to develop assays.

The companies are working on two initial projects. The first is the co-development of a CDx to identify prostate cancer patients with Homologous Recombination Repair (HRR) gene mutations in China, the EU and Japan.

The next project is the development of a CDx to identify breast cancer patients with BRCA gene mutations in the EU for Lynparza (olaparib) monotherapy.

Li-Mou Zheng, PhD, Founder and Chairman of AmoyDx, said, “We are very pleased to announce today that we are further developing our partnership with AstraZeneca by entering into a master collaboration agreement. AmoyDx is a trustworthy CDx co-development partner with rich expertise in R&D, Regulatory Affairs and Commercialization globally. AmoyDx and AstraZeneca share the common core value of prioritizing patients, and we will work together to accelerate the contribution for the benefit of patients.”


Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like